CrystecPharma opens R&D facility in Haimen City, China
Haimen Biopharmaceutical Technology Entrepreneurship Park
Facility will support UK-based crystal and particle engineering specialist's existing Chinese subsidiary to expand product development services
CrystecPharma has opened a new research and development facility in Haimen City, Jiangsu Province, China, the UK-based pharmaceutical development firm said Wednesday.
The new facility at Haimen Science and Technology Park was established after Crystec participated in the Yangtze Delta Advanced Drug Development platform, jointly funded by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Haimen government.
The platform, which has received GBP 550 million equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by pharmaceutical excipients and drug delivery technologies.
Crystec said its proprietary mSAS supercritical fluid technology will play a key role in enabling the development of new therapeutics, creation of value-added medicines, and in simplification of formulations and manufacturing processes.
“This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China,” said Dr. Qun Shao, Crystec’s Chief Operations Officer.
The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology, and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.
Related News
-
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile... -
News AstraZeneca invests billions in manufacturing facilities in China
Landmark investment will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China, contributing to AstraZeneca's 2030 goals.
-
News WuXi Biologics accomplishes automated continuous drug substance production at pilot-scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale.
-
News EU Commission to restrict Chinese companies in medical devices procurement
The European Commission, the primary executive arm of the EU, announced their decision to exclude Chinese companies from EU government purchases of medical devices exceeding EUR€5 million in a bid to rebalance trade barriers. -
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery.